Regeneron just dropped $2.3 billion on a company that started in a rented lab corner with an $8 curtain protecting its equipment. Parabilis Medicines isn't building traditional ADCs; it's engineering spy-like peptides that slip inside cells and neutralize "undruggable" cancer targets from within.
A Corner Lab, a Floral Curtain, and a Billion-Dollar Handshake
Parabilis Medicines started in a rented corner of a lab in Newton, Massachusetts. The founders protected their mass spectrometer with an $8 floral curtain because it sat too close to a safety shower. They had no venture capital. No fancy headquarters. Just a wild idea about a new kind of drug.
Fast forward to May 2026, and Regeneron just signed a deal worth up to $2.3 billion to get access to that idea. The antibody-drug conjugate (ADC) market is red hot, but this isn't a traditional ADC. It's something weirder, more ambitious, and potentially more powerful.
What Regeneron Actually Bought
The deal breaks down like this: Regeneron pays $50 million upfront and commits another $75 million to invest in Parabilis's next equity round. On top of that sits up to $2.2 billion in milestone payments tied to five initial drug targets, plus tiered royalties in the low-double-digit range.
Regeneron gets to discover new drugs alongside Parabilis, then takes over development, manufacturing, and worldwide sales once candidates mature. They can also add more targets later by paying additional option fees. It's a classic "let someone else prove the science, then we'll scale it" pharma playbook.
But here's why this deal stands out from the dozens of ADC partnerships inked over the past two years: Parabilis isn't making ADCs. Not exactly.
The Helicon: A Drug That Acts Like a Spy
Traditional ADCs work like guided missiles. An antibody finds a cancer cell, locks onto its surface, gets swallowed up, and then releases a toxic payload inside. The payload is basically poison; it kills any rapidly dividing cell it touches. The antibody just makes sure the poison arrives at the right address.
Parabilis's Helicon platform is fundamentally different. Think of it less like a missile and more like a spy who infiltrates a building, finds the exact person causing trouble, and neutralizes them without blowing up the whole floor.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Helicons are stabilized peptides (tiny protein-like molecules) shaped into rigid spirals. They're small enough to slip through cell membranes on their own, like a small molecule. But they're large and structured enough to grab onto flat protein surfaces inside the cell, like an antibody would. They sit in a sweet spot between two worlds.
Once inside, they can do three things: block a specific protein interaction, recruit the cell's garbage disposal system to destroy a target protein, or deliver a radioactive payload for imaging or treatment. Same scaffold, three different jobs. That versatility is what makes pharma executives write very large checks.
Why This Isn't Just Another ADC Deal
The global ADC market hit roughly $15 billion in 2025 and is growing at double-digit rates. Big pharma has been on a shopping spree: Pfizer swallowed Seagen for $43 billion. AbbVie grabbed ImmunoGen for $10.1 billion. Johnson & Johnson picked up Ambrx for $2 billion.
But most of these deals involve variations on the same theme: better linkers, stronger poisons, more precise targeting of the cell surface. Regeneron is playing a different game. Rather than compete in the crowded traditional ADC space, they're building a portfolio of next-generation conjugate platforms that attack problems from new angles.
In April 2026, they partnered with Telix Pharmaceuticals on radiopharmaceutical conjugates (antibodies carrying radioactive payloads). They've worked with CytomX on tumor-activated bispecifics that only turn on inside tumors. And now Parabilis gives them Helicons, which can target "undruggable" proteins that no ADC payload has ever been able to hit specifically.
Regeneron's strategy is clear: skip the me-too ADC race and build a toolkit of modalities nobody else has.
Parabilis Hits the Public Markets (and Breaks Records)
Days after announcing the Regeneron collaboration, Parabilis filed for an IPO. Not a modest one, either. The company ultimately raised approximately $670 million, setting a record for a biotech IPO on Nasdaq. Its valuation landed near $2.3 billion.
With around $957 million in pro forma cash (including the Regeneron equity investment), Parabilis has enough runway to fund what comes next: a global Phase 3 trial for its lead drug, zolucatetide, in patients with desmoid tumors. That trial is expected to start in the first half of 2027.
Zolucatetide blocks the interaction between beta-catenin and TCF, two proteins that drive the Wnt signaling pathway. When Wnt goes haywire, cells grow out of control. This pathway has been a "white whale" target in oncology for decades because the proteins involved have flat, featureless surfaces that traditional drugs can't grip. Helicons can.
The Team Behind the Curtain (Literally)
Parabilis was founded in 2015 by Gregory Verdine (a Harvard chemistry professor whose lab invented Helicons), WeiQing Zhou, Sir David Lane, and John McGee. They bootstrapped it without VC money until the science was mature enough to attract serious capital.
Once it did, the money came fast. Series C brought in $107 million. Series D, $178 million. Series E (led by Nextech Invest), $145 million. Series F: a massive $305 million. All told, Parabilis raised over $800 million in private venture capital from firms like ARCH Venture Partners, Fidelity, GV (Google Ventures), and RA Capital.
In 2023, the company brought in Mathai Mammen as CEO, a physician-scientist who previously ran global R&D at Johnson & Johnson and oversaw 19 approved medicines across his career. That's the kind of hire you make when you're done being a scrappy lab startup and ready to become a commercial-stage company.
The Bigger Picture
Regeneron's $2.3 billion bet isn't just about Parabilis. It's a signal that the ADC revolution is entering its next phase. The first wave proved that guided missiles work. The second wave optimized the explosives. The third wave (happening now) is asking: what if the payload isn't a bomb at all, but a precision tool?
With over 290 ADC drugs tracked in competitive landscapes and hundreds of clinical trials running simultaneously, differentiation is everything. Parabilis offers Regeneron something genuinely novel: the ability to hit intracellular targets that every other approach has failed to reach.
For a company that started with an $8 curtain and a dream, that's not a bad outcome.
Funding & Financings
4 min read
Denmark's $861M Bet to Become Europe's Biotech Capital
The Novo Nordisk Foundation just made its largest donation ever: $861 million over a decade to turn Denmark's BioInnovation Institute into a European biotech powerhouse. The catch? It's not just about drugs anymore.
